Table 3. Half-life estimates for initial gp41 IgA decline in AHI (exponential decay model) for individuals with at least a 2-fold decrease in antibody response.
|
HIV-1 gp41 IgA |
||||
|---|---|---|---|---|
|
Half-life (days) |
Fold decreasea |
|||
| Estimate | 95% CI | Estimate | 95% CI | |
| Plasma (N=10) | 48.19 | 34.57, 61.81 | 8.65 | 3.38, 13.93 |
| Mucosal (N=11) | 2.71 | 2.06, 3.36 | 6.20 | −0.51, 12.92 |
AHI, acute HIV-1 infection; CI, confidence interval; Ig, immunoglobulin.
The model that fit best for the mucosal samples assumes a lower asymptote greater than zero (antibody response plateaus at a non-zero level), whereas the model for the plasma samples assumes that the lower asymptote is zero (antibody response eventually declines all the way to zero).
a
At lower asymptote for mucosal and 150 days post peak for plasma.